Shilpa Medicare gets Health Canada GMP approval for Jadcherla facility
Karnataka: Shilpa Medicare has recently announced that the Company's finished dosage form manufacturing facility, Unit IV, situated at Pharma SEZ, Jadcherla, Telangana, has received Health Canada GMP approval.
The inspection was conducted from September 12, 2022, to September 16, 2022.
The facility is involved in the manufacturing, packaging, labelling, and testing of finished dosage forms (sterile injections and oral solids) for the treatment of cancer and adjuvant therapy.
This GMP approval will allow the company for the commercial distribution of products in Canada and enable new application submissions to Health Canada.
"This approval reaffirms the company's focused efforts to maintain the GMP status up to the standards of global regulatory authorities," Shilpa Medicare said in a BSE filing.
Read also: Shilpa Medicare Hyderabad division gets USFDA clearance
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.